COPD-associated pulmonary Hypertension: clinical implications and current methods for treatment
Standard
COPD-associated pulmonary Hypertension: clinical implications and current methods for treatment. / Grimminger, Jan; Ghofrani, Hossein-Ardeschir; Weissmann, Nobert; Klose, Hans; Grimminger, Friedrich.
In: EXPERT REV RESP MED, Vol. 10, No. 7, 07.2016, p. 755-66.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - COPD-associated pulmonary Hypertension: clinical implications and current methods for treatment
AU - Grimminger, Jan
AU - Ghofrani, Hossein-Ardeschir
AU - Weissmann, Nobert
AU - Klose, Hans
AU - Grimminger, Friedrich
PY - 2016/7
Y1 - 2016/7
N2 - INTRODUCTION: Chronic obstructive pulmonary disease is the fourth leading cause of death worldwide, one serious complication being pulmonary hypertension, which occurs in up to 30% of patients and increases mortality drastically. Difficulties in diagnosis and the unclear beneficial effects of PH-specific therapy have hitherto resulted in the absence of approved therapies. Consequently, PH and right heart failure in COPD are still currently treated according to symptoms and not underlying cause Areas covered: This review focuses on the current knowledge of its pathogenesis, clinical picture, diagnosis as well as methods for treatment Expert commentary: Since PH-COPD is an orphan disease with grievous consequences, and diagnosis as well as the right choice of possible treatment is crucial, referral to an expert center in cases of suspicion is necessary. Hitherto there is no officially approved treatment available even though several studies have shown notable improvement in selected individuals, making diagnostics, prognostic markers, and the search for therapeutic agents key issues of interest in this field.
AB - INTRODUCTION: Chronic obstructive pulmonary disease is the fourth leading cause of death worldwide, one serious complication being pulmonary hypertension, which occurs in up to 30% of patients and increases mortality drastically. Difficulties in diagnosis and the unclear beneficial effects of PH-specific therapy have hitherto resulted in the absence of approved therapies. Consequently, PH and right heart failure in COPD are still currently treated according to symptoms and not underlying cause Areas covered: This review focuses on the current knowledge of its pathogenesis, clinical picture, diagnosis as well as methods for treatment Expert commentary: Since PH-COPD is an orphan disease with grievous consequences, and diagnosis as well as the right choice of possible treatment is crucial, referral to an expert center in cases of suspicion is necessary. Hitherto there is no officially approved treatment available even though several studies have shown notable improvement in selected individuals, making diagnostics, prognostic markers, and the search for therapeutic agents key issues of interest in this field.
KW - Journal Article
U2 - 10.1080/17476348.2016.1190275
DO - 10.1080/17476348.2016.1190275
M3 - SCORING: Journal article
C2 - 27212458
VL - 10
SP - 755
EP - 766
JO - EXPERT REV RESP MED
JF - EXPERT REV RESP MED
SN - 1747-6348
IS - 7
ER -